Abstract There is little evidence to direct the management of malignant paragangliomas (mPGL) beyond initial surgical treatment. Peptide receptor radionuclide therapy (PRRT), using somatostatin analogues, is effective in other neuroendocrine tumours, but data on its efficacy in treating mPGL are scarce. We report safety and efficacy outcomes from a case series of five patients with advanced mPGLs treated with 177 Lu-DOTATATE PRRT. The mean age of our cohort was 34 years (range 16-47); 4 patients were male with bone disease being the most prevalent metastatic site. PRRT scheme varied between 1 and 4 cycles, with premature cessation due to suspected pneumonitis in one case and disease progression in another. Three patients with previously documented progressive disease achieved stabilization following treatment; one had partial response and one was treatment refractory. Median progression-free survival was 17 months (range 0-78 months). 177-Lu-DOTATATE is an effective therapy in mPGLs in this molecularly defined patient cohort, warranting further investigation in larger studies including hereditary and sporadic mPGL.
Introduction
Phaeochromocytomas (PCC) and paragangliomas (PGL) are rare neuroendocrine tumours (NETs) arising from adrenal (80 %) or extra-adrenal (20 %) chromaffin tissue, respectively [4] . Whilst most PCC/PGLs are benign, with surgical excision frequently curative, malignant progression occurs in 10-20 % of patients, either due to metastatic spread at diagnosis or recurrence after radical treatment [11] . Though malignancy may be predicted by germline mutations in the succinate dehydrogenase (SDH) complex or adverse histology [3, 13] , there is currently little evidence to guide the follow-up of these patients, which is decided on a case-by-case setting. Crucially, no specific intervention exists to modulate the risk of malignant progression in high-risk individuals [12] .
Invariably, systemic spread confers a poor prognostic outlook and shifts the focus of treatment interventions from curative to palliative. Moreover, since metastatic paragangliomas (mPGL) are a rare entity, the evidence supporting their optimal management beyond surgical resection is limited. Nevertheless, unlike gastroenteropancreatic neuroendocrine tumours (GEPNETs), mPGLs are mostly non-functioning with a low proliferation rate and without local mass effect; patients are often paucisymptomatic from their disease; this tends to convey fairly extended survival times even in the context of metastatic disease. The decision to initiate active anticancer treatment over watchful waiting/best supportive care is therefore challenging, particularly in the context of a peculiar palliative population where 5-year overall survival rates often exceed 60 % [5] .
Radionuclide therapy with [
131 I]-meta-iodo-benzyl-guanidine ([   131   I ]-MIBG) for mPGL has been in use since the 1980s, producing radiologic responses in a third of patients and disease stabilization in 43 % [1] , with median survival times of 4.7 years [15] . However, significant adverse events including hypertension, hypothyroidism, gastrointestinal and haematological toxicity limit the utility of this treatment [5] . Recently, the novel peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogues, such as 177 Lu-DOTA-TATE, has been proposed and found to be well tolerated with high efficacy in these NETs [10] .
PRRT exposes tumour cells to a beta-emitting isotope linked to a chelating agent, DOTATATE, whose peptide component binds somatostatin receptors (SSTR) on their cell membrane. Its selectivity is conferred by the overexpression of SSTRs, in particular SSTR-2, in NETs.
Previous studies have demonstrated the efficacy of this treatment in SSTR-positive GEPNETs with an overall disease control rate of 82 % with durable responses confirmed by a median time to radiologic progression of 36 months [9] . Similar results have emerged with the use of 90 Y-DOTATOC [8] . Nonetheless, most data justifying the use of PRRT in mPGL are extrapolated from case series including many patients with GEPNETs [6, 7] , whose history, symptoms and, crucially, distribution of somatostatin expression markedly differ from that of mPGLs [14] . To date, there is limited published evidence about long-term outcomes in patients with mPGLs [2] . Here, we describe the clinical experience of a tertiary referral centre with a specialist NET board by reporting a case series of five consecutive cases of mPGL treated with 177 Lu-DOTATATE PRRT for advanced disease.
Patients and methods
In this retrospective study, we reviewed treatment records of all patients with neuroendocrine malignancies treated with PRRT at Imperial College London between 2008 and 2014 and identified five consecutive patients with histologically confirmed mPGL. Complete pre-treatment disease features and blood tests were documented.
Patients were staged by computed tomography (CT), in combination with 68 Ga-DOTATATE positron emission tomography (PET) and MIBG scans. Genetic testing for the major PCC/PGL susceptibility genes (SDH-B, D, VHL and RET) was offered to patients aged \40.
Indication and eligibility for treatment was multidisciplinary evaluation. PRRT was delivered as outpatient treatment and followed standard practice. No immediate adverse events were noted immediately after treatment. Treatment cycles were repeated with a 12-week interval, with patients being given a maximum of 4. Response to treatment was assessed by surveillance imaging with CT and PET following each cycle.
Overall survival (OS) was defined as the time between diagnosis of mPGL and the most recent follow-up or death, and PFS as the time between initiation of 177 Lu-DOTA-TATE PRRT treatment and radiologically proven disease progression.
Statistical analysis
Fisher's exact test was used to determine any associations between variables. Kaplan-Meier statistics and Cox regression were used for univariate analyses of survival. All statistical analysis was conducted using STATA 13 (STATACorp., College Station, TX, USA). For all other analyses, a significance level of 0.05 was adopted.
Results
A summary of the clinicopathologic characteristics of the patient population is provided in Table 1 . At study baseline, all patients presented with evidence of catecholamine excess and carried a germline mutation in the SDH-B gene, causing familial paraganglioma syndrome. Other presenting symptoms included pain (40 %), weight loss (20 %) and cauda equina syndrome (20 %). In 20 % of the cohort, the tumour was primarily malignant, whereas 80 % had a metastatic recurrence of a previous mPGL. The number of metastatic sites ranged between 1 (60 %) and 3 (40 %), with bone spread being the most common metastatic site.
Mean serological characteristics prior to treatment, such as full blood count, albumin and liver function tests, were collected and analysed. Mean haemoglobin levels were low prior to starting treatment, with anaemia noted in 20 % of the cohort. Mean albumin and liver function tests were within normal limits. Univariate analysis using a Cox proportional hazard regression model of serological characteristics did not reach a significant association with overall survival within the mPGL cohort.
Patients received 177 Lu-DOTATATE PRRT at between 6.6 and 7.6 GBq per session (Table 1) .
Clinically relevant adverse events were documented in two patients. These included suspected iatrogenic pulmonary toxicity in one case and reactive swelling of tumour metastases causing a painful flare requiring escalation of analgesia. In both cases, subsequent 177 Lu-DOTATATE PRRT treatments were delayed.
Response to treatment included one partial response (20 %), with imaging following each treatment showing good uptake within target lesions and a significant reduction in size of the large retroperitoneal mass (Fig. 1a, b) . Disease stabilization was achieved in three patients (60 %), and one patient (20 %) had primarily progressive disease through treatment. At the time of reporting, 60 % of patients were alive with disease and 40 % have died of their disease. Patients within the group did not reach a median overall survival (Fig. 1c) . Mean OS was 53 months (SD 22.7 months) and mean PFS was 36.4 months (SD 27.4 months).
Discussion
There is very limited evidence to support the use of PRRT in mPGL, mainly as a consequence of the rarity of the disease and the limited overall accessibility to PRRT outside of tertiary referral centres. In a previous case series including a range of SSTR-positive tumours, 12 PGLs were treated with PRRT with cumulative doses ranging between 14.8 and 29.6 GBq. The median time to progression was not reached following a median follow-up of 13 months, whilst radiologic restaging after treatment showed one partial response, disease stabilization in six patients and disease progression in another three [17] . However, in this report, 25 % of patients had non-metastatic PGL and only 33 % displayed documented evidence of progressive disease prior to PRRT; this may have affected estimates of response and survival outcomes due to the favourable prognostic outlook of such patients.
In our study, we report treatment outcomes of a consecutive series of unselected progressive mPGL treated with PRRT following multidisciplinary discussion at the c Kaplan-Meier curve to demonstrate the probability of survival over months in the mPGL cohort Imperial College NET board. Treatment with PRRT resulted in partial response in one and disease stabilization in three patients who had a background of progressive metastatic PGL, qualifying with an overall radiologic disease control rate of 80 %. Furthermore, in one patient whose disease progressed through treatment, there was encouraging radiologically proven disease control of target lesions. The overall survival of our cohort ranges from 26 to 84 months, with three patients being in active follow-up following treatment. The progression-free survival ranges from 1 to 78 months, confirming the bioactivity of PRRT in our patient group. Importantly, our patient population was exclusively composed of succinate dehydrogenase B (SDH-B) mutation carriers, a highly prevalent genetic trait indicative of aggressive malignant progression of PCC/ PGL [16] . It would be important in future studies to verify the PFS advantage of PRRT in sporadic mPGLs, where the natural course might be more indolent.
The safety profile of PRRT in our population is similar to that reported in previous studies. No treatment-related deaths were observed, and only a single case of significant toxicity with a plausible association with treatment, pulmonary toxicity, was identified.
The limited number of cases, their heterogeneous pattern of disease progression and the single-centre, retrospective nature of our study limit the strength of our observations. Similarly, due to the retrospective design, we lack formal assessment of quality of life measures, something warranting further evaluation given the palliative nature treatment. Nevertheless, such limitations are common studying a rare condition like mPGLs.
To conclude, our experience suggests that PRRT is an effective and tolerable therapy in mPGLs, a finding that warrants further investigation in larger patient cohorts, where the precise positioning of PRRT in relation to other systemic anticancer treatments should be evaluated.
